Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak
... successfully block the entry of H5N1 virus into, replication in, and excretion from chickens. Another ... a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been ... produce a pandemic. Furthermore, the H5N1 rapid replication cycle which began in 1996 now appears to be over. ...Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic
... radiation. Simultaneously, a therapeutic cascade is initiated by product replication resulting in tumor vasculature shutdown and anti-tumoral immune attack. ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...Purdue researcher invents molecule that stops SARS
... Ind. - A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the ... specific protein, called papain-like protease, or PLpro, involved in viral replication and evasion of the immune system," said Ghosh who has a joint appointment ...Replidyne Announces Second Quarter 2008 Results From Operations
... discovery research programs, primarily the C. difficile and DNA replication inhibition programs, offset by decreased expense related to the REP8839 ... the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research. The Company's ...Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
... to a new and potent class of integrase inhibitor drugs that blocks viral replication by preventing viral genes from integrating into the DNA of newly infected ... in the absence of drug, PhenoSense Integrase also provides a measure of replication capacity (RC) of integrase inhibitor sensitive and resistant viruses. ...Replidyne Announces 2007 Fourth Quarter and Full Year Results
... research programs, primarily its C. difficile and inhibition of DNA replication programs offset by decreased expense related to the REP8839 program that ... the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research. Safe Harbor ...FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over
... mortality characteristics are expected to subside - until the next rapid replication cycle of this or another influenza virus strain begins. 140,000 virus ... whose concentration has been shown to be related quantitatively to rapid replication and epidemics. FluForecast(R) is a product and service of Replikins Ltd. ...International team identifies 480 genes that control human cell division
... of activation in cancer cells. Malignant cells have lost control of the replication process, so detecting differences in cell cycle gene activation in normal ... in Israel. Rather than cycling on and off as normally occurs when cell replication and development proceeds, these genes are expressed in a steady state or ...Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
... factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing. "This patent represents a ...Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
... SPC3649-HCV SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and the Company ...Cynvec to Present at The 2009 New York Venture Summit
... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and ...Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre- clinical models of ovarian and ...Cynvec to Present at the BIO National Venture Conference
... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and ...Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
... disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. In HCV care, the device inhibits viral replication through selective elimination of HCV in circulation and assists to preserve immune cells by removing toxic proteins shed from the surface of HCV. ...AcroMetrix Announces the Release of OptiQuant-S Hepatitis C Virus (HCV) Panel
... RNA viruses like HCV or HIV. This new technology allows insertion of synthetic sequences into a mammalian RNA virus which were shown to be stable in replication and capable of forming infectious RNase resistant virus particles. This new proprietary system can be used for designing defined RNA positive ...Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
... is undergoing worldwide development as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. ...Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
... is undergoing worldwide development as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. ...Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
... knowledge, the first quantitative measures of virus structural change ever shown to correlate with and to precede virus outbreaks. Cycles of rapid replication of the virus with increasing replikin counts appear to be a means of virus expansion into new host populations and geographic areas, and of ...Jennerex Appoints Samantha Miller as Vice President of Corporate Development
... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
... for hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit http://www.genelabs.com . Cowen and Company was the exclusive financial advisor to ...deCODE genetics Announces Third Quarter 2008 Financial Results
... by deCODE and others, contribute to the incidence of an estimated 60 percent of all breast cancers. The test integrates data from discovery and replication studies published in major peer-reviewed journals and involving nearly 100,000 breast cancer patients and healthy volunteers from many ...Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
... Medical Officer of Romark Laboratories. -- "Potential Role for Nitazoxanide in Combination with STAT-C Agents for the Inhibition of HCV replication Without the Development of Resistance," Korba, et al. Sunday Nov. 2, 5:30 PM PST (Oral Session #115) This oral presentation by Brent ...